Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs The Virtual NP

Two GLP-1 desks, one scoreboard. We put CoreAge Rx and The Virtual NP head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 149 · Grade C

The Virtual NP

Visit The Virtual NP Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 69 on our six-factor Brief Score — The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

That doesn't make The Virtual NP a bad call — it's best for patients in served states wanting affordable visits and fda-approved branded glp-1s. Weigh the six factors below against your own priorities before you decide.

Why CoreAge Rx leads: it's our #1 on the board — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
44
Supply Reliability
95
73
Transparency
90
80
Access Breadth
93
62
Clinical Oversight
92
87
Track Record
88
82
CoreAge RxBrief Score 94 · 69The Virtual NP

Price, coverage & the tracker

CoreAge RxThe Virtual NP
Brief Score94/100 (A)69/100 (C)
Semaglutide$149/moFrom $75/mo (brand Wegovy, medication billed separately)
Tirzepatide$349/moFrom $75/mo (brand Zepbound, medication billed separately)
CoverageAll 50 states7 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: Flat rate held for a third straight cycle — no first-month teaser to reset.

The Virtual NP: New to the tracker on 1 August 2026. The published line reads From $75/mo (brand Zepbound, medication billed separately) at our first reading; there is no earlier reading of ours to compare it against yet.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.